isoxazoles has been researched along with imatinib mesylate in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| George, D | 1 |
| Häyry, P; Savikko, J; Von Willebrand, E | 1 |
| Archer, SL; Michelakis, ED | 1 |
| Ashihara, E; Kimura, S; Maekawa, T; Ohyashiki, K; Okabe, S; Tauchi, T | 1 |
| Chen, LT; Chiang, NJ; Hsueh, YS; Li, CF; Shih, NY; Yen, CC | 1 |
| Chang, HH; Chen, LT; Chiang, NJ; Hsueh, YS; Li, CF; Yen, CC | 1 |
2 review(s) available for isoxazoles and imatinib mesylate
| Article | Year |
|---|---|
Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Isoxazoles; Leflunomide; Ligands; Male; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction | 2001 |
An evidence-based approach to the management of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Benzamides; Bosentan; Calcium Channel Blockers; Comorbidity; Dichloroacetic Acid; Drug Therapy, Combination; Epoprostenol; Evidence-Based Medicine; Fluoxetine; Humans; Hypertension, Pulmonary; Iloprost; Imatinib Mesylate; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins, Synthetic; Pulmonary Artery; Purines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Simvastatin; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents | 2006 |
4 other study(ies) available for isoxazoles and imatinib mesylate
| Article | Year |
|---|---|
Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection.
Topics: Alkynes; Angiogenesis Inhibitors; Animals; Benzamides; Blood Vessels; Constriction, Pathologic; Dihydroorotate Dehydrogenase; Graft Rejection; Imatinib Mesylate; Immunosuppressive Agents; Isoxazoles; Male; Nitriles; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Wistar; Recurrence; Tunica Intima; Uridine; Vascular Diseases | 2003 |
Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen.
Topics: Animals; Benzamides; Cell Line, Tumor; Fusion Proteins, bcr-abl; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Isoxazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutagenesis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Resorcinols | 2011 |
Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Autophagy; Benzamides; Benzoquinones; Cell Death; Cell Extracts; Cell Line, Tumor; Down-Regulation; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Isoxazoles; Lactams, Macrocyclic; Models, Biological; Phosphorylation; Piperazines; Proteolysis; Proto-Oncogene Proteins c-kit; Pyrimidines; Resorcinols | 2013 |
MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzamides; Cell Death; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunohistochemistry; Inhibitory Concentration 50; Isoxazoles; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Necrosis; Neoplasm Transplantation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Resorcinols; RNA Interference; RNA, Small Interfering; Sirolimus; TOR Serine-Threonine Kinases | 2014 |